BioSig Technologies, Inc. (BSGM): History, Ownership, Mission, How It Works & Makes Money

Does the name BioSig Technologies, Inc. still defintely represent a medical device company, or has its $13.80 million market capitalization found a new direction entirely? The answer is a dramatic pivot: following its May 2025 merger with Streamex Exchange Corporation, the company is now focused on Real World Asset (RWA) tokenization, aiming for a piece of the staggering US$142.851 trillion global commodity market. This strategic shift comes as the company reported a Q1 2025 net loss of $(2.800) million on just $0 million in revenue, leaving you to weigh the legacy of the PURE EP™ System against the potential of the new digital gold play. How do you analyze a company that completely changes its mission mid-year?

BioSig Technologies, Inc. (BSGM) History

You're looking at a company with two distinct lives: a medical device innovator and a real-world asset (RWA) tokenization platform. BioSig Technologies, Inc.'s history isn't a straight line; it's a story of a dramatic, high-stakes pivot in 2025. It started in medical technology, developing the PURE EP™ System for better heart signal visualization, but a strategic merger and a massive capital raise this year completely changed its focus to digital commodities.

Given Company's Founding Timeline

Year established

BioSig Technologies, Inc. was incorporated in 2009.

Original location

The company was initially incorporated in Nevada, USA.

Founding team members

The company's initial vision was driven by founder Kenneth L. Londoner.

Initial capital/funding

Early funding, typical for a development-stage medical technology firm, came through private placements and convertible notes to support initial research and product development before accessing public markets.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The most defintely transformative period for BioSig Technologies, Inc. happened in 2025, marking a complete shift from a medical device company to a financial technology (FinTech) player focused on blockchain. This wasn't a minor change; it was a full pivot.

The company's legacy business, the PURE EP™ Platform, was deprioritized following the merger with Streamex Exchange Corporation in mid-2025. The financial reality of the medical device path was tough, with Q1 2025 reporting $0 million in total revenue and a net loss of $(2.800) million. That's a stark indicator of the need for change.

The new strategy centers on real-world asset (RWA) tokenization, starting with gold. This pivot was immediately backed by significant capital, which is the real game-changer:

• Secured up to $1.1 billion in growth financing in July 2025, structured as a $100 million in senior secured convertible debentures and a $1 billion Equity Line of Credit.
• Closed an underwritten public offering in August 2025, raising approximately $15 million specifically for purchasing gold bullion and corporate growth.

This massive influx of capital and the shift in focus to commodities tokenization-a market estimated at $142 trillion-fundamentally re-rated the company, pushing its market capitalization to approximately $0.21 Billion USD as of November 2025. You can see how this pivot impacts the balance sheet and future outlook by Breaking Down BioSig Technologies, Inc. (BSGM) Financial Health: Key Insights for Investors.

BioSig Technologies, Inc. (BSGM) Ownership Structure

The ownership and control of BioSig Technologies, Inc. have fundamentally shifted as of November 2025, following its transformative acquisition of Streamex Exchange Corporation and subsequent corporate rebrand to Streamex Corp. (NASDAQ: STEX). The new structure effectively transfers control to the former Streamex shareholders, solidifying the company's pivot from medical technology to institutional-grade commodity tokenization, a significant strategic change.

This is a reverse merger, so the new business focus and controlling shareholders are what matter now.

Given Company's Current Status

The entity formerly known as BioSig Technologies, Inc. is now a publicly traded company called Streamex Corp., trading on the Nasdaq Capital Market under the ticker symbol STEX. The acquisition of Streamex Exchange Corporation closed on November 4, 2025, a transaction that involved the issuance of approximately 109,070,079 new shares of common stock, causing massive dilution for legacy BioSig shareholders. This transaction included the issuance of one share of Super Voting Preferred Stock, a mechanism that grants effective control over the combined company to the former Streamex shareholders, regardless of the common stock split.

Given Company's Ownership Breakdown

The new ownership structure is dominated by the shareholders of the acquired entity, as outlined in the merger terms. Former Streamex stockholders became the controlling interest through both significant common stock issuance and a special voting share.

What this estimate hides is the complexity of the one Super Voting Preferred Stock; it means the 75% common stock figure is defintely the controlling block. For a deeper dive into who holds shares, consider Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

Given Company's Leadership

The strategic direction of Streamex Corp. is now steered by the executive team from the acquired entity, focusing on real-world asset tokenization and digital finance. This new leadership reflects the company's complete business model pivot in late 2025.

• Henry McPhie: Chief Executive Officer (CEO) and Co-Founder. He leads the company's mission to bring commodities on-chain through blockchain solutions.
• Morgan Lekstrom: Chairman and Co-Founder. He guides the vision of tokenizing real-world assets, bringing expertise in capital markets and commodities.
• Mitchell Williams, CFA: Chief Investment Officer (CIO). He brings over 20 years of Wall Street experience to the investment management strategy.
• Ferdinand Groenewald: Interim CFO & Principal Accounting Officer.

The average tenure of this new management team is quite short, suggesting a new team is in place to execute the new strategy. This is a high-conviction, high-risk pivot for the organization.

BioSig Technologies, Inc. (BSGM) Mission and Values

BioSig Technologies, Inc.'s core purpose has undergone a dramatic shift in 2025, pivoting from a medical device focus to becoming a financial technology firm centered on real-world asset (RWA) tokenization. The company's mission now is to transform global commodity finance, a move that redefines its cultural DNA beyond its original healthcare aspirations.

Given Company's Core Purpose

The company, now operating primarily through its subsidiary, Streamex Exchange Corporation (Streamex), is no longer driven by improving cardiac ablation procedures; it is now focused on digitizing physical assets. This is a high-risk, high-reward strategy, especially considering the company reported a Q2 2025 Earnings Per Share (EPS) of -$0.74, missing consensus estimates, and minimal revenue with nearly no sales in 2025 YTD as of mid-year. You need to understand this pivot before looking at their financials.

Official mission statement

The new mission is squarely focused on the intersection of commodities and blockchain technology, aiming to solve old problems in a legacy industry. The shift is defintely a full pivot, not just a rebrand.

• Unlock liquidity, transparency, and accessibility across the $142 trillion commodities market.
• Build a company grounded in gold bullion as a trusted store of value, enabling a scalable, high-return business model through tokenization.
• Bridge the gap between traditional finance and the digital economy for investors and institutions worldwide.

Vision statement

The company's vision is aggressive and reflects its new identity as a financial technology platform, not a medtech firm. They are aiming for leadership in a new, rapidly evolving space.

• Establish the company as a Nasdaq-listed leader in the gold bullion-based real-world asset space.
• Revolutionize commodity finance by developing primary issuance and exchange infrastructure for on-chain commodity markets.
• Accelerate shareholder value creation by leveraging a new capital strategy, which included securing a $1.1 billion funding commitment in July 2025.

Given Company slogan/tagline

While the old medical device tagline was 'Clarity in Sight™,' the new focus is less about an explicit slogan and more about a core action: bringing tangible assets into the digital age. They are building the infrastructure for the future of finance.

• Bringing commodity markets on chain.
• Tokenization technology powering the modern commodities market.

To be fair, the original mission to improve patient outcomes with the PURE EP™ System was compelling, but the financial reality-like the Q1 2025 net loss of -$2.8 million-forced a hard change. Now, the mission is financial disruption. You can learn more about the stakeholders driving this new direction by Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

BioSig Technologies, Inc. (BSGM) How It Works

BioSig Technologies, Inc. now operates with a dual focus, having fundamentally pivoted from solely being a medical technology company with its PURE EP™ Platform to a financial technology firm following its May 2025 merger with Streamex Exchange Corporation, which led to a corporate rebrand to Streamex Corp. in September 2025. This means the company now delivers value to two distinct markets: cardiac electrophysiology labs and the emerging Real World Asset (RWA) tokenization market, primarily for commodities.

Given Company's Product/Service Portfolio

Given Company's Operational Framework

The company's operations have split, reflecting its new dual business model. On the MedTech side, the focus has shifted from extensive commercial distribution of hardware to a leaner model centered on research and development (R&D) of novel software algorithms for the PURE EP™ Platform. That's a smart way to cut cash burn.

On the FinTech side, the core operations involve building and scaling the Real World Asset (RWA) tokenization infrastructure. This includes securing the underlying assets-like the plan to use net proceeds from the August 2025 public offering to purchase gold bullion-and developing the on-chain exchange technology.

• MedTech R&D: Developing new software to enhance the PURE EP™ Platform's capabilities, particularly for pulsed field ablation (PFA) treatment specificity.
• FinTech Infrastructure: Building institutional-grade primary issuance and decentralized exchange for commodity tokenization.
• Treasury Management: Executing a gold-backed treasury management strategy, which was funded in part by an August 2025 public offering that raised approximately $15.02 million in gross proceeds.

Here's the quick math: the company reported 2025 Q1 revenue of $0 million and a net loss of $(2.800) million, so the Streamex merger and the pivot to RWA tokenization is defintely a high-stakes move to change the financial trajectory. You can learn more about the shift by Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

Given Company's Strategic Advantages

The company now holds a unique, albeit high-risk, position by straddling two high-growth but disparate markets. Its strategic advantages stem from this proprietary technology and the timing of its market pivot.

• Proprietary MedTech IP: BioSig Technologies, Inc. maintains a patent portfolio of 41 issued/allowed patents for its PURE EP™ signal processing technology, which has shown in clinical studies to provide a 75% overall improvement in signal quality over conventional systems.
• First-Mover in Commodity RWA: Streamex is positioned as an early mover in bringing the multi-trillion-dollar commodities market, starting with gold, onto the blockchain, which can unlock new financing and liquidity for real-world assets.
• Gold-Backed Treasury: The strategic decision to hold gold bullion as a treasury asset provides a tangible, non-fiat backing to the new FinTech model, attracting a different class of institutional investor.
• Established Clinical Footprint: The PURE EP™ Platform is installed in major US health systems, including Mayo Clinic-Phoenix and Cleveland Clinic, providing a valuable, albeit secondary, source of clinical validation and potential future revenue.

BioSig Technologies, Inc. (BSGM) How It Makes Money

BioSig Technologies, Inc. is in a state of radical transition, so its revenue model has shifted from selling a medical device to pursuing a high-risk, high-reward strategy in digital commodities. The company currently generates virtually no operating revenue, but its future financial engine is designed to earn fees from the tokenization and trading of real-world assets, starting with gold.

BioSig Technologies, Inc.'s Revenue Breakdown

To be clear, as of the nine months ended September 30, 2025, BioSig Technologies, Inc. reported $0 in total revenue from operations. The minimal trailing twelve months (TTM) revenue of approximately $0.01 million USD stems from the legacy medical device business. The table below reflects the intended future revenue streams from the new business model, which is currently in the pre-revenue development stage.

Business Economics

The core economic reality for BioSig Technologies, Inc. is a pivot from a capital-intensive medical device model to a technology-driven financial services model, a massive change. The old model centered on high-margin sales of the PURE EP™ System, a capital equipment purchase for hospitals, plus potential recurring revenue from disposables. That business is now deprioritized.

The new business economics, following the merger with Streamex Exchange Corporation, rely on the following fundamentals:

• Real-World Asset Tokenization: The goal is to digitize (tokenize) physical commodities, initially gold, onto a blockchain platform. The company expects to earn fees on the issuance, custody, and trading of these digital assets.
• Treasury Management Strategy: A key driver is the use of a $1.1 billion financing commitment to purchase physical gold bullion, which will serve as the underlying asset for the tokenization platform. This creates a balance sheet-driven strategy, not a traditional sales-driven one.
• High Operating Burn: Despite the revenue vacuum, the company is burning cash to build the new platform and manage the legacy operations. The shift is high-risk because the new platform must achieve rapid adoption and scale to justify the substantial upfront capital and operating expenses.

Here's the quick math: the company is trading a long, expensive sales cycle for a medical device for a potentially faster, but still unproven, path to transaction-based revenue in the digital finance space. Breaking Down BioSig Technologies, Inc. (BSGM) Financial Health: Key Insights for Investors

BioSig Technologies, Inc.'s Financial Performance

The financial performance as of the third quarter of 2025 (Q3 2025) reflects a company in a deep developmental and transitional phase, not a commercial one. Honestly, the numbers show a business fighting for survival and betting everything on the new pivot.

• Total Revenue (Q3 2025 YTD): $0. This is the most critical number, signifying the complete halt in commercial momentum for the legacy business and the pre-revenue status of the new digital platform.
• Net Loss (Q3 2025 YTD): The net loss for the nine months ended September 30, 2025, was a significant $38.8 million. This loss is driven by operating expenses and a $10.2 million loss from remeasuring a derivative liability related to the Streamex acquisition.
• Liquidity and Going Concern: As of Q3 2025, the company had a working capital deficit of $111 million. Management has explicitly disclosed substantial doubt about the company's ability to continue as a going concern, which is a defintely serious red flag for investors.
• Cash Position: Cash increased to $11.0 million as of Q3 2025, largely due to financing activities, but operating cash outflow was still $7.4 million for the nine-month period. They need to start generating revenue, and fast.

BioSig Technologies, Inc. (BSGM) Market Position & Future Outlook

BioSig Technologies, Inc. (which rebranded to Streamex Corp. in September 2025) is undergoing a radical pivot, shifting from a niche medical device company to a dual-focus entity, strategically centered on Real World Asset (RWA) tokenization while maintaining its PURE EP™ Platform business. This new direction, backed by a potential $1.1 billion in growth financing, positions the company as a high-risk, high-reward play in both the stable electrophysiology market and the volatile, emerging digital asset space.

Frankly, the company's future trajectory is now less about its PURE EP™ System and more about its ability to execute on its new gold-backed treasury and RWA tokenization strategy.

Competitive Landscape

The competitive analysis must now reflect a dual market presence. In electrophysiology (EP), BioSig Technologies is a small, innovative player challenging giants. In the new RWA tokenization space, the company is a first-mover among public companies, making direct comparison difficult. Here's the quick math on the EP side, which is the historical core.

Opportunities & Challenges

The company's strategic pivot in 2025 creates a distinct set of near-term opportunities and risks that investors defintely need to map out. The new focus is a significant departure from the medical device sector's typical growth path.

Industry Position

BioSig Technologies, Inc., now operating as Streamex Corp., has effectively traded a position as an innovative but sub-scale MedTech player for a speculative, emerging role in the financial technology sector.

In the electrophysiology market, the PURE EP™ System remains a highly-regarded, FDA 510(k)-cleared technology, but its commercialization has been slow, with the company reporting only $0 million in revenue for the first quarter of 2025.

• EP Market: The company is a technology leader in signal fidelity, not a market share leader, operating in a global market expected to reach over $10 billion by 2025.
• RWA Tokenization Market: The new focus aims to bring the approximately $142 trillion commodities market onto the blockchain, starting with gold.
• Strategic Shift: The merger and rebrand signal a pivot to a 'gold treasury company' model, using the medical device business as a secondary operation.

You can learn more about the institutional interest in this new direction by reading Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

The core challenge is managing a dual strategy with high capital demands; the company is attempting to innovate in both cardiac care and global finance simultaneously. The immediate action for you is to assess the viability of the RWA tokenization business, as that is now the primary driver of the company's valuation and risk profile.